Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer
- 1 July 2017
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 109, 28-35
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI (R21 CA194662)
- Career Development Award from the Colorado Lung Cancer SPORE (NIH/NCI P50 CA058187)
- American Cancer Society Institutional Research Grant (ACS IRG 57-001-53)
- University of Colorado Cancer Center Lung Head and Neck Program (CCSG P30 CA046934)
This publication has 38 references indexed in Scilit:
- Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patientsRespiratory Research, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease ProgressionJournal of Clinical Oncology, 2011
- Smad4 Inactivation Promotes Malignancy and Drug Resistance of Colon CancerCancer Research, 2011
- Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammationJournal of Clinical Investigation, 2009
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Participation of DNA repair in the response to 5-fluorouracilCellular and Molecular Life Sciences, 2008
- Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerGenes & Development, 2006